Movement Disorders

A patient whose oral regimen has been optimized about as far as it can go, weighing a subcutaneous infusion pump against one more bounded round of oral adjustment before committing to it.

A patient whose rescue injections work when he can administer them — the real problem is administering them during the exact episodes they are meant to treat.

A new-onset seizure in a patient on high-dose carbidopa/levodopa, matching a pattern the FDA flagged in a March 2026 safety warning.

A medication started specifically to delay dyskinesia has produced a different, unanticipated harm, and stopping it is not as simple as it sounds.

A newly diagnosed 47-year-old choosing between two first-line strategies whose real tradeoff plays out over a career, not a single clinic visit.

Three weeks after deep brain stimulation surgery, his medication doses are already being reduced — the question is how quickly that reduction should continue.

Three drugs, one shared mechanism, and one shared warning that carries different weight in Huntington’s disease than in almost any other condition.

The better-studied first-line drug for tremor carries a real respiratory risk for this specific patient, and the alternative has its own real tolerability problem.

A treatment that worked reliably for years has started failing faster with every cycle, and the reason changes which drug comes next.

The same drug and the same mechanism, and two patients who can tolerate wildly different doses of it, for reasons the team has to make explicit rather than assume.

A new diagnosis, two chelators, and a real difference in early neurological risk between them for her specific presentation.

A tremor with no structural cause, and a patient who wants to know plainly whether medication has any real role in her treatment.